Atai Life Sciences (ATAI) News Today → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free ATAI Stock Alerts $1.84 -0.03 (-1.60%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineatai Life Sciences investee Beckey Psytech starts dosing patients in second part of treatment-resistant depression studyproactiveinvestors.com - April 24 at 8:48 AMatai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depressionfinance.yahoo.com - April 24 at 7:24 AMatai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depressionglobenewswire.com - April 24 at 7:00 AMatai Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of Psychopharmacologystockhouse.com - April 18 at 10:32 PMatai Life Sciences reports positive Phase 1 results for BPL-003investing.com - April 18 at 10:32 PMatai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacologyfinance.yahoo.com - April 17 at 10:44 AMatai announces publication of Beckley Psytech's Phase 1 study for novel 5-MeO-DMT assetproactiveinvestors.com - April 17 at 9:16 AMAtai Life Sciences N.V. (ATAI) Price Target Decreased by 15.35% to 10.90msn.com - April 17 at 5:44 AMatai Life Sciences CEO Florian Brand spotlights psychedelic therapy milestones and upcoming catalystsproactiveinvestors.com - April 15 at 4:22 PMAtai Life Sciences executive sells $114k in company stockinvesting.com - April 6 at 8:13 AMAre You Looking for a Top Momentum Pick? Why atai Life Sciences N.V. (ATAI) is a Great Choicemsn.com - April 4 at 1:53 PMAtai Life Sciences upgraded at Maxim on Beckley investmentmsn.com - April 3 at 3:43 PMUT Tyler University Academy senior directs first student-led theater productionmsn.com - April 2 at 1:43 AMCould We Ever Have Sci-Fi Tech Like the ‘Star Trek’ Transporter? A New Roddenberry Entertainment Podcast Finds Outmsn.com - April 1 at 3:38 PMAtai Life Sciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lagfinance.yahoo.com - April 1 at 3:38 PMAtai Life Sciences Q4 And Full-Year 2023 Results: Steep Cash Drain Yet 2026 Target Remains, Update On Psychedelic Pipelinemsn.com - March 29 at 11:10 AMIntranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depressionmsn.com - March 28 at 8:08 PMRecap: ATAI Life Sciences Q4 Earningsbenzinga.com - March 28 at 2:48 PMatai Life Sciences funded into 2026; sets sights on key milestones for its psychedelic therapiesproactiveinvestors.com - March 28 at 8:45 AMATAI Life Sciences GAAP EPS of -$0.12 beats by $0.04msn.com - March 28 at 7:53 AMatai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlightsglobenewswire.com - March 28 at 7:00 AMatai-backed Beckley Psytech unveils positive results from DMT for treatment-resistant depression studyproactiveinvestors.com - March 27 at 8:40 AMAtai Life: Beckley Psytech's Phase 2a Trial Of BPL-003 Positive In Treatment Resistant Depressionmarkets.businessinsider.com - March 27 at 8:10 AMatai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depressionfinance.yahoo.com - March 27 at 8:10 AMatai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depressionglobenewswire.com - March 27 at 7:00 AMThinking about buying stock in Lexicon Pharmaceuticals, Cassava Sciences, Clearside Biomedical, Lantern Pharma, or ATAI Life Sciences?morningstar.com - March 15 at 4:32 AMCaris Life Sciences to Showcase Research at 2024 SGO Annual Meeting on Women's Cancerfinance.yahoo.com - March 14 at 1:30 PMPsychedelic drug ibogaine hailed as healing. U.S. patients ask why it’s illegal.msn.com - March 14 at 1:30 PMatai Life Sciences advances VLS-01 for treatment-resistant depressionfinance.yahoo.com - March 12 at 1:49 PMATAI Apr 2024 1.500 putfinance.yahoo.com - March 8 at 1:49 PMATAI Apr 2024 2.000 callfinance.yahoo.com - March 8 at 8:49 AMatai Life Sciences doses first patient in Phase 1b study of its optimized oral DMT formulationproactiveinvestors.com - March 4 at 8:59 AMatai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01globenewswire.com - March 4 at 8:00 AMatai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conferenceglobenewswire.com - February 28 at 5:00 PMATAI Life Sciences Stock (NASDAQ:ATAI), Quotes and News Summarybenzinga.com - February 22 at 6:30 PMATAI Mar 2024 2.000 callfinance.yahoo.com - February 17 at 1:17 AMATAI Feb 2024 1.500 putfinance.yahoo.com - February 15 at 8:06 PMATAI Mar 2024 1.500 putfinance.yahoo.com - February 15 at 10:06 AMATAI Aug 2024 1.500 callfinance.yahoo.com - February 15 at 12:01 AMBreaking: The US FDA Just Granted Priority Review of an MDMA Treatment for PTSDtheglobeandmail.com - February 14 at 7:01 PMATAI Life Sciences Announces New CFO Appointment and Transitionmsn.com - February 7 at 10:52 AMAtai Life Sciences Names Anne Johnson CFOmarketwatch.com - February 6 at 9:21 PMatai Life Sciences Appoints Anne Johnson as Chief Financial Officerfinance.yahoo.com - February 6 at 9:21 PMMeet the family leading the psychedelic revolutionmsn.com - February 2 at 10:04 AMAtai buys 35.5% stake in psychedelic drug developer, stock rallies 18%msn.com - January 6 at 12:36 PMEcstasy-for-Medicine Advocate Raises $100 Millionfinance.yahoo.com - January 5 at 8:51 AMatai Life Sciences expands its pipeline with $50M investment in Beckley Psytechca.investing.com - January 4 at 5:12 PMAtai Invests $50M In Beckley Psytech For Short-Duration Psychedelics Developmentmsn.com - January 4 at 5:12 PMAtai Life Sciences Shows Positive Results In Phase 1 Clinical Study For PTSD Treatmentmsn.com - January 4 at 5:12 PMBerliner Psychedelika-Firma Atai kauft Anteil an Beckley Psytechbloomberg.com - January 4 at 12:11 PM Get Atai Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ATAI and its competitors with MarketBeat's FREE daily newsletter. Email Address “Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers. Find out why right here (and see what you can do to get in too with just a few dollars). ATAI Media Mentions By Week ATAI Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATAI News Sentiment▼0.470.39▲Average Medical News Sentiment ATAI News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATAI Articles This Week▼42▲ATAI Articles Average Week Get Atai Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ATAI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: NATR News Today FBLG News Today ESPR News Today ANRO News Today ADCT News Today AMRN News Today RANI News Today URGN News Today PGEN News Today ORGO News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATAI) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsYour Money is Not SafeAmerican AlternativeFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atai Life Sciences Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
